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Abstract
Colorectal cancer (CRC) is one of the leading malignant cancers with a rapid increase in incidence and mortality. The
recurrences of CRC after curative resection are sometimes unavoidable and often take place within the first year after
surgery. MicroRNAs may serve as biomarkers to predict early recurrence of CRC, but identifying them from over 1,400
known human microRNAs is challenging and costly. An alternative approach is to analyze existing expression data of
messenger RNAs (mRNAs) because generally speaking the expression levels of microRNAs and their target mRNAs are
inversely correlated. In this study, we extracted six mRNA expression data of CRC in four studies (GSE12032, GSE17538,
GSE4526 and GSE17181) from the gene expression omnibus (GEO). We inferred microRNA expression profiles and
performed computational analysis to identify microRNAs associated with CRC recurrence using the IMRE method based on
the MicroCosm database that includes 568,071 microRNA-target connections between 711 microRNAs and 20,884 gene
targets. Two microRNAs, miR-29a and miR-29c, were disclosed and further meta-analysis of the six mRNA expression
datasets showed that these two microRNAs were highly significant based on the Fisher p-value combination (p=9.14610
29
for miR-29a and p=1.14610
26 for miR-29c). Furthermore, these two microRNAs were experimentally tested in 78 human
CRC samples to validate their effect on early recurrence. Our empirical results showed that the two microRNAs were
significantly down-regulated (p=0.007 for miR-29a and p=0.007 for miR-29c) in the early-recurrence patients. This study
shows the feasibility of using mRNA profiles to indicate microRNAs. We also shows miR-29a/c could be potential biomarkers
for CRC early recurrence.
Citation: Kuo T-Y, Hsi E, Yang I-P, Tsai P-C, Wang J-Y, et al. (2012) Computational Analysis of mRNA Expression Profiles Identifies MicroRNA-29a/c as Predictor of
Colorectal Cancer Early Recurrence. PLoS ONE 7(2): e31587. doi:10.1371/journal.pone.0031587
Editor: Steve Horvath, University of California, Los Angeles, United States of America
Received July 16, 2011; Accepted January 9, 2012; Published February 13, 2012
Copyright:  2012 Kuo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Kaohsiung Medical University Hospital (KMUH98-8I04) (http://www.kmuh.org.tw/), Excellence for Cancer
Research Center Grant through funding by the Department of Health, Executive Yuan, Taiwan, Republic of China (DOH100-TD-C-111-002) (http://science.doh.gov.
tw/), and the National Science Council of the Republic of China (NSC 99-2320-B-037-014-MY3 and NSC 94-2314B037-104) (http://www.nsc.gov.tw/). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hjuo@kmu.edu.tw (S-HHJ); cy614112@ms14.hinet.net (J-YW)
Introduction
Colorectal cancer (CRC) is one of the leading malignant cancers
with more than 500,000 deaths worldwide every year [1,2]. The
incidence and mortality of CRC in Chinese have been increasing
rapidly in the past decades [3]. Presently the effective treatment for
CRC is curative resection of the tumor with chemotherapy, but
recurrences are sometimes unavoidable [4]. Among the patients
with recurrence, 40%–50% of them take place in the first year
after initial surgical resection, and more than 90% happen within
four years [5]. The tumor stage and pathological characteristics
are commonly used to predict the prognosis and facilitate
treatment for CRC patients in practice. Thus far, there are no
available biomarkers to predict the recurrence of CRC.
Recently, microRNAs have been shown to be important factors to
regulate many gene functions in human cancers [6], and microRNAs
have been proposed as novel biomarkers for cancers [7]. Previous
studies have shown that microRNA expression is altered in various
types of cancers including CRC [8,9]. MicroRNAs are endogenous
short non-coding RNAs that can bind to the 39 untranslated regions
(UTRs) of their target messenger RNAs (mRNAs). They act as post-
transcriptional regulators of gene expression [10] through transla-
tional repression and/or mRNA degradation in many biological
processes including development, cell differentiation, cell prolifera-
tion, apoptosis and metabolism [11,12]. These processes are usually
involved in tumorigenesis [13]. Although several studies have
reported an association between microRNAs and CRC development
[14,15,16,17], the role of microRNAs in predicting CRC recurrence
has been barely investigated.
Up to October 2011, more than 1,400 human microRNAs have
been reported [18,19]. It is challenging, time-consuming and costly
to evaluate the functional consequence of every microRNA in
relation to CRC recurrence. Computational approaches have been
developed to obtain more information from mRNA expression data
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31587[20,21,22,23]. It is generally believed that the expression levels of
most microRNAs and their direct mRNA targets are inversely
correlated because microRNAs exert translational repression or
degradation mechanism [21,24]. Accordingly microRNA expres-
sion profiles can be inferred from mRNA expression data by
bioinformatics approaches. Recently, the IMRE method has been
proposed [22] to predict microRNA expression by utilizing mRNA
datasets and microRNA target databases. In this study, we obtained
six mRNA expression datasets of CRC patients from the gene
expression omnibus (GEO). We used computational analysis and
meta-analysis to predict microRNAs related to CRC recurrence,
especially early recurrence. Furthermore we used our human CRC
samples to validate these candidate microRNAs.
Materials and Methods
Search strategy for mRNA datasets from GEO
In October 2010, we searched the GEO (http://www.ncbi.nlm.
nih.gov/geo/) for studies that provided mRNA expression data of
CRC patients. The search terms were ‘‘colorectal cancer’’ or
‘‘CRC’’ in combination with ‘‘human [organism]’’. In total, 110
studies were initially identified. We then limited the number of
studies by the keywords of ‘‘recurrence’’ and ‘‘relapse’’ in their
abstracts, among which four studies (GSE12032, GSE17538,
GSE4526 and GSE17181) were extracted. We used the originally
defined recurrence in these four studies. The recurrence was
commonly defined as a local recurrence or distant metastasis of
CRC within the follow-up period, and the follow-up lengths of
these studies ranged between 45.9 and 68.6 months. The
GSE17181 and GSE4526 data only reported distant metastasis
but the other two datasets did not specify which type of recurrence
in their data. We downloaded their normalized mRNA expression
data and sample information from the GEO. The GSE17538 and
GSE4526 studies used the same gene expression platform (HG-
U133Plus 2.0) whereas the other two studies used two distinct ones
(AceGene Human Oligo Chip 30 K and Agilent-014950 CGH
Microarray). Detailed information of these downloaded datasets is
summarized in Table 1.
Filtering out study subjects and probes in datasets
The downloaded datasets included CRC patients with various
tumor stages: stage II in GSE17181, stage III in GSE4526, and
stages I–IV in GSE12032 and GSE17538. We only selected the
patients with tumor stage II and stage III because they together
accounted for a majority of CRC patients (,70%) [25], and those
with stage I and IV provided little information. Therefore, a total
of six stage-specific datasets (three stage II and three stage III
datasets) were created for further analysis. Since these datasets
used platforms with different probes to detect mRNA expression,
we performed the quality control for these datasets using the below
two criteria. First, we discarded the probes with the inter quartile
range (IQR) lower than the median of the total probe-set’s IQR in
order to remove the less differentially expressed probes. Secondly,
if a gene was interrogated by multiple probes, one with the highest
IQR value was retained and the rest was removed. After the
filtering procedure, more than half the genes were filtered out in
each of these datasets (Table 1).
Computational analysis by IMRE to infer putative
microRNAs
The IMRE method (http://www.lussierlab.org/IMRE) has
been developed to impute microRNA expression levels from
mRNA expression data based on weighted and ranked expression
levels and putative microRNA targets [22]. This method assumes
an inverse correlation between the expression of microRNAs and
their direct mRNA targets [26,27]. While applying IMRE method
to each data, we identified a set of either up-regulated or down-
regulated microRNAs. Using this method, a score representing
microRNA’s expression level was calculated based on six
downloaded mRNA expression datasets and MicroCosm Targets
that is a microRNA target database (see the below section of
‘‘Target prediction database’’ for details). The detailed procedures
were as follows: (1) mRNA in each study subject was ranked by its
expression level, and then scored according to its rank using the
OrderedList method [28] of Bioconductor [29], and (2) the
expression score of each microRNA in each subject was imputed
by calculating the difference between the mean of weighted rank
scores of its target genes and non-target genes.
Target prediction database
To predict gene targets for a given microRNA, we downloaded
the latest target prediction database from MicroCosm Targets,
formerly called miRBase targets [30,31] (MicroCosm Targets
version 5; http://www.ebi.ac.uk/enright-srv/microcosm/) and
retrieved 568,071 predicted microRNA-target connections be-
tween 711 human microRNAs and 20,884 gene targets.
MicroCosm Targets uses the miRanda algorithm that is one of
the first miRNA target prediction algorithms and one of the most
widely used algorithms. The algorithm was based on a dynamic
program to search for maximal local complementarity alignments.
To validate the MicroCosm database, we compared the results
between MicroCosm Targets and miRNome that was used in
Table 1. The datasets for computation analysis after preprocessing and quality control.
Study Stage Number of sample Follow-up period Platform Number of Probes Published
Recurrence/Non-
recurrence (months) All After QC years
GSE12032 II 30/62 .45.9 AceGene Human Oligo Chip 30 K(GPL1291) 29640 9297 2009
a
GSE12032 III 47/59 .45.9 AceGene Human Oligo Chip 30 K(GPL1291) 29640 9297 2009
a
GSE17538 II 6/17 68.6 (median) HG-U133Plus 2.0 (GPL570) 54675 13594 2009 [44]
GSE17538 III 15/16 60 (median) HG-U133Plus 2.0 (GPL570) 54675 13594 2009 [44]
GSE17181 II 16/24 73 (mean) Agilent-014950 CGH Microarray (GPL8841) 42426 10630 2010 [45]
GSE4526 III 13/23 54 (median) HG-U133Plus 2.0 (GPL570) 54675 13056 2010 [46]
aCitation is missing or the study has not been published.
doi:10.1371/journal.pone.0031587.t001
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TargetScan [33] to validate the candidate microRNAs suggested
by MicroCosm database. The MicroCosm database yielded the
majority of microRNAs (including the causal one) that were found
by the original study [22] (Table S1). Another advantage to use
MicroCosm Targets was that the latest version (targets release
version v5) contains more microRNAs than the miRNome
(generated in 2007). Accordingly, we used the MicroCosm
database for the subsequent studies.
Statistic analysis
After calculating the score that represents the expression levels of
each microRNA for each study subject, we listed potential
microRNAs that could distinct the recurrence from non-recurrence
of the CRC patients. For each microRNA, an empirical p value was
obtained using 1000 permutations. The cutoff p value to select
potential microRNAs was set to be equal to or less than 0.1. We
used this liberal value in order to reduce a type II error in the initial
analysis. The analysis was performed using the R statistical package
with Bioconductor package twilight [34,35].
To reduce a type I error, we further combined the results of the
six datasets using meta-analysis for the initially selected micro-
RNAs. The Cochran’s Q statistic was used to test for heterogeneity
among these datasets. The meta-analysis was performed based on
the effect size (the difference in predicted scores between the
recurrent and non-recurrent CRC patients) and standard error.
An overall effect size and the 95% confidence interval (95% CIs)
were reported. To identify the most significant microRNA with
the smallest global p value and to further increase the power, we
performed a joint analysis by combining raw p values based on the
Fisher’s combination of p-values [36] with the cutoff p value of
5610
25 (,0.05/711, 711 microRNAs).
Bench experiments to confirm the findings
To verify the candidate microRNAs indicated by the above
computational method and meta-analysis, we further collected 78
CRC tumor tissues at the Kaohsiung Medical University Hospital.
The clinicopathologic characteristics of these 78 patients are
shown in Table S2. These samples were obtained surgically from
the CRC patients with UICC stages I–III and snap frozen in
liquid nitrogen at 280uC. To avoid the potential influence of
neoadjuvant treatment on microRNA expression, all the patients
did not undergo neoadjuvant treatment, chemotherapy or
radiotherapy before surgery. A written informed consent was
obtained from each patient and the study protocol was approved
by the Institutional Review Board of the Kaohsiung Medical
University Hospital. These 78 patients were clustered into early
recurrence (43 cases) and non-early recurrence groups (35
controls). There is no significant difference in age and sex between
the two groups. Early recurrence was defined as local recurrence
(tumor growth restricted to the anastomosis or the region of the
primary operation) or distant metastasis (distant metastasis or
diffuse peritoneal seeding) within 1 year after radical resection
[5,24,37]. Non-early recurrence was defined as no recurrence
within 1 year. Notably, some of non-early recurrent patients may
have recurrence as the follow-up continues.
Approximately100 mgoftissue was homogenizedusinga bench-
top homogeniser (Polytron PT1600E, Kinematica AG, Lucerne,
Switzerland) in 1 mL of TRIzol reagent (Invitrogen) and purified
with Qiagen RNAeasy Columns (Qiagen). We extracted and
purified total RNAs from each tumor tissue, and TaqMan
microRNA RT-qPCR (Applied Biosystems) assays were used to
quantify the microRNA expression level. Real-time PCR was
carried out using the Applied Biosystems 7500 Sequence Detector
System. All real-time PCR reactions were run in triplicates. U6b
was used as the internal control because it is a commonly used
internal control for microRNA expression normalization and also
because U6bhasbeenshown relatively stable based on ourin-house
data. The relative expression level of a microRNA was calculated
using the equation, log10(2
2DCt), where DCt=(CTmiR2CTU6b).
The mean of log10(2
2DCt) and its standard deviation (SD) were also
calculated. We compared the difference in the microRNA
expression levels between the early and non-early recurrent groups
by independent t-test and multiple ANCOVA analysis with
adjustment for age, sex and stage of tumor. Our experimental data
were divided into two groups according to the median of each miR-
29a and miR-29c data. The Kaplan-Meier method was used to
detect the relationship between the relapse time after surgery and
dichotomized miRNAs expression. The significance level was set at
0.05. The statistical analyses were performed using SAS9.1.
Results
Identification of miR-29a and miR-29c as candidate
microRNAs for CRC recurrence
By applying the IMRE method to the six independent CRC
mRNA microarray datasets, we identified four microRNAs (miR-
29a, miR-29c, miR-100 and miR-627) in the stage II datasets and
three microRNAs (miR-29a, miR-29c and miR-363) in the stage
III datasets with a p value x 0.1(Table 2). Among them, miR-29a
and miR-29c were indicated in both stage II and III datasets.
Figure 1 shows that miR-29a had a higher score in the recurrent
patients (indicated as 1) than the non-recurrent patients (indicated
as 0) in all six datasets. Because the score was calculated from a set
of miR-29a target genes’ expression values, a higher score means
that these target genes were up-regulated in the recurrence group.
In other words, the inverse correlation between a microRNA and
its target gene indicated that miR-29a was down-regulated in the
recurrence group and thus it may play a role as a tumor suppressor
of CRC. The similar pattern was also observed for miR-29c (data
not shown). In this study, we did not identify any up-regulated
microRNA reaching our defined cutoff point (P x0.1) between
the recurrent and non-recurrent patients in all six datasets.
Table 2. Association between microRNAs and CRC
recurrence of the stage II and III CRC patients in the different
datasets.
Stage II
GSE17181
(n=40)
GSE12032
(n=92)
GSE17538
(n=23)
MiR p value p value p value
hsa-miR-29a 0.08 ,0.01 0.02
hsa-miR-29c 0.01 ,0.01 0.03
hsa-miR-100 0.04 ,0.01 0.02
hsa-miR-627 0.04 ,0.01 0.02
Stage III
GSE4526
(n=36)
GSE12032
(n=106)
GSE17538
(n=31)
MiR p value p value p value
hsa-miR-29a 0.05 ,0.01 0.08
hsa-miR-29c 0.09 0.01 0.10
hsa-miR-363 0.02 0.05 0.05
doi:10.1371/journal.pone.0031587.t002
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We performed meta-analysis to assess the intensity of the
associations between the two microRNAs and recurrence of CRC
(Figure 2). Using meta-analysis, we expected to obtain overall and
more reliable results. The random effect model showed an effect
size of 213.36 (95% CI: 147.38–279.34) for miR-29a and an effect
size of 176.91 (95% CI: 111.63–242.18) for miR-29c. Indeed, the
fixed effect model also yielded identical results. Fisher’s combina-
tion of p-values showed p=9.14610
29 for miR-29a and
p=1.14610
26 for miR-29c. There was not significant between-
dataset heterogeneity for the two microRNAs (p=0.59 for miR-
29a and p=0.69 for miR-29c).
We then further analyzed the mRNAs and their pathways in
relation to CRC recurrence to gain more insight to the disease
pathogenesis. First, we listed top 10 pathways enriched with miR-
29a/29c target genes (Table S3). Then, we listed the top target
genes which are most significantly associated with CRC
recurrence in the GEO dataset (Tables S4). CDC42, which is
involved in 3 major pathways (see Table S3), was significantly
different between recurrent and non-recurrent patients (combined
p=0.00053).
miR-29a and miR-29c expression level in CRC samples
We further collected 43 CRC patients of early recurrence and 35
patients of non-early recurrence to validate miR-29a and miR-29c in
regard to the prediction of CRC early recurrence. We found that both
miR-29a and miR-29c had significantly lower expression levels in the
early recurrence group than non-early recurrence group (both p values
were 0.007 after adjusting for sex, age and cancer stage). Both
microRNAs remained significant even after excluding the 10 subjects
(8 non-early subjects and 2 early subjects) of cancer stage I (Table 3).
Our empirical results agreed with the findings from the computational
analysis based on mRNA microarray datasets, indicating that the two
microRNAs play an important role in the early recurrence of CRC. In
the Kaplan-Meier analysis, we showed that either a high level of miR-
29a or miR-29c had a better survival at 12
th month, but only miR-29a
could significantly predict the early recurrence (Figure S1). The failure
of prediction bymiR-29cin the Kaplan-Meier analysis maybe due to a
short follow-up or an inappropriate cutoff due to a small sample size.
Discussion
The study of microRNAs has begun a new era for better
understanding of disease mechanisms. However, the role of
Figure 1. Up-regulation of genes targeted by miR-29a in the recurrence group in the six datasets. The y axis is a score representing the
expression levels of miR-29a and the x axis is the groups with and without recurrence of CRC. The group ‘‘1’’ refers to the recurrence group and ‘‘0’’
refers to the non-recurrence group. The score was calculated from a set of miR-29a targeted genes’ expression values, a higher score means that
these targeted genes were up-regulated in the recurrence group ‘‘1’’.The similar pattern was found for miR-29c.
doi:10.1371/journal.pone.0031587.g001
Identify miRNA to Predict CRC Recurrence In Silico
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31587microRNAs in recurrence of CRC is still not clear. In this study,
we identified miR-29a and miR-29c as important candidates by
employing an ingenious method that prioritized candidate
microRNAs from publicly available genome-wide gene expression
datasets. Using meta-analysis on publicly available datasets and
experimental confirmation, we directly measured and validated
miR-29a and miR29c as predictors for CRC early recurrence. To
our knowledge, these two microRNAs have not been reported to
be related to early recurrence of CRC.
To infer microRNA expression, we applied the IMRE method
by combination of microRNA target prediction and mRNA
expression data. The main advantage of this method is to access
public mRNA expression datasets for the identification of putative
microRNAs related to the diseases of interest. However a robust
estimation for microRNA expression also depends on a reliable
target prediction database. Here we used MicroCosm Targets for
the prediction of microRNA target genes. We did not use the
union of combining different prediction algorithms, such as
miRNome, because it is likely to reduce the power due to many
falsely predicted targets. In addition to MicroCosm Targets, we
also used another two prediction databases, miRanda [32] (August
2010 release with good mirSVR score, conserved microRNA) and
TargetScan [33]. miR-29a and miR-29c were also indicated by
these two microRNA predictive software to be involved in CRC
recurrence, which indicated the robustness of the IMRE method.
However, the significance level was lower by using miRanda
(p=0.0173 for miR-29a and p=0.00197 for miR-29c in p value
combination) than MicroCosm Targets (p=9.14610
29 for miR-
29a and p=1.14610
26 for miR-29c). The reason may be due to
more predicted targets by miRanda than MicroCosm Targets.
Figure 2. The results of meta-analysis for miR-29a and miR-29c in the six datasets. In the meta-analysis, effect size (the difference in
predicted scores between the recurrent and non-recurrent CRC patients) and standard error were calculated for each study. An overall effect size and
95% confidence intervals (95% CIs) were reported with p values estimated based on the Fisher’s combination of p-values [36].
doi:10.1371/journal.pone.0031587.g002
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between microRNAs and several common diseases, but it is still
expensive to conduct a genome-wide expression array to disclose
disease related microRNAs. Although using bioinformatic tools such
as the IMRE method can reduce the number of candidates and
prioritize these candidates, a large number of false positives are
inevitable.Inthepresentstudy,wefoundthatsomehighlysignificant
microRNAs predicted via this computational analysis in one dataset
could not be replicated in other datasets. Instead of using the
conservative Bonferroni correction, we analyzed several datasets to
identify the consistent microRNAs to reduce the type I error. The
experimentofhuman samples further confirmed the insilico finding.
Our results indicate that down-regulation of miR-29a and miR-
29c is associated with the early recurrence of CRC. The down-
regulation of the miR-29 family has been reported in various
human cancers including lung cancer [38], prostate cancer [39]
and invasive breast cancer [40]. A recent study has shown that
miR-29 is involved in the p53 pathway, an important tumor
suppressor regulator [41]. MiR-29 activates p53 and induces
apoptosis via suppression of CDC42 and p85a [41]. Our analysis
for miR-29 targets suggested that CDC42 (combined p val-
ue=0.00053 in Table S4) and other mRNAs are likely to be
involved in the potential pathway of CRC development. In
addition, the mutant form of p53 was observed in 51–74% of all
CRC and other human tumors [42]. The above studies offer a
biological plausibility to support the role of miR-29 family in
suppressing CRC recurrence.
In addition to microRNAs, the recurrence of CRC could be also
influenced by the tumor stages and the period of follow-up. In the
computation analysis, we only focused on the CRC patients with
tumor stage II and stage III because they represented the majority
of CRC patients. Only few patients at stage I developed
recurrence and most of patients at stage IV developed recurrence
after surgery leading to less useful information for our study.
Although our empirical study used early recurrence (i.e.
recurrence takes place within 1 year after surgery) as the
phenotype of interest, recent reports indicated that 40–50% of
recurrences become apparent within the first year after initial
resection, and the time from the initial treatment to recurrence is
strongly related to survival [43] Our experimental results from the
human samples of early recurrence agreed with the finding from
the computational analysis that was based on patients for a follow-
up of 3–6 years, which indicates that our experimental finding is
less likely to be influenced by the follow-up length.
We validated miR-29a and miR-29c as biomarkers for CRC
early recurrence. The other three microRNAs (miR-100, miR-627
and miR-363) were also identified by the computational analysis
but they were only significant in patients of either stage II or stage
III. Therefore they were not further investigated in the present
study due to a lower priority than miR-29. Our limited number of
experimental samples also may not provide a sufficient power to
analyze these two microRNAs that are only significant in one
cancer stage. Given that our main purpose of this study is to show
the feasibility of this computational approach to identify useful
microRNAs, without analyzing these three potential microRNAs
would not significantly reduce the scientific contribution of our
study.
In conclusion, this study showed an efficient strategy by
combining the in silico analysis and the empirical experiment to
suggest microRNA-29a and microRNA-29c as potential biomark-
ers to predict early recurrence of CRC. Using these biomarkers
may allow health providers and patients to take a more efficient
way to prevent CRC recurrence. In addition, our study also
provides a direction to further investigation to the mechanism of
recurrent CRC.
Supporting Information
Figure S1 Subjects were dichotomized to have high or
low microRNA levels according to the median of 1.39 for
miR-29a and 0.58 for miR-29c. The solid line indicates the
high level group and dash line means low level group.
(DOC)
Table S1 Significant microRNAs with p-values and false
discovery rate(FDR) [1,2] by miRNome and MicroCosm
Targets in GSE6631. The majority of significant microRNAs
(including the causal one, miR-204, indicated by underscore line)
were shown by both of the two target prediction database,
miRNome and MicroCosm Targets, in GSE6631.
(DOC)
Table S2 Clinicopathologic characteristics of the 78
colorectal cancer patients.
(DOC)
Table S3 Top 10 enriched pathways with miR29a or
miR29c target genes analyzed by MetaCore pathway
analysis system.
(DOC)
Table 3. miR-29a and miR-29c expression levels in our CRC samples of early recurrence and non-early recurrence.
Non-early recurrence Early- recurrence Crude Adjusted
n=27 n=41
mean ± sd mean ± sd p value p value{
Age 68.0613.0 65.2613.9 0.409
Female, n (%) 11 (40.7) 17 (41.5) 0.953
stage
2 19 (54.3) 18 (41.9) 0.047
3 8 (22.9) 23 (53.5)
miR-29a{ 1.5760.51 1.2560.49 0.019 0.020
miR-29c{ 0.8160.49 0.5060.44 0.009 0.009
{p value was calculated with adjustment for age, sex and stage of CRC tumor by ANCOVA analysis.
{The relative expression levels of miR-29a and miR-19c (U6b as internal control) were calculated by log10(2
2DCt).
doi:10.1371/journal.pone.0031587.t003
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genes with recurrence of CRC in the datasets.
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